SCHEMBL2742896

SCHEMBL2742896

CNCCCC(=O)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2022572 0.97 LMNA (0.46)
SCHEMBL19267180 0.92 LMNA (0.46)
SCHEMBL15306198 0.91 TSHR (0.48)
SCHEMBL14073785 0.90 KDM4A (0.47)
SCHEMBL13595584 0.90 KDM4A (0.47)
SCHEMBL13063685 0.90 KDM4A (0.47)
SCHEMBL464448 0.83
SCHEMBL18477609 0.83 LMNA (0.43)
SCHEMBL5909180 0.83 LMNA (0.57)
SCHEMBL7753090 0.83 LMNA (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265620-A1 NOVEL CAMPTOTHECIN DERIVATIVE, COMPOSITION CONTAINING SAME, AND USE THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2023-10-25 EP disclosed
US-20230331760-A1 ARYL GLUCOSIDE DERIVATIVE AND USE THEREOF IN DRUG SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) 2023-10-19 US disclosed
EP-4186888-A1 COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ModernaTX, Inc. (US) 2023-05-31 EP disclosed
US-11332491-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2022-05-17 US disclosed
EP-3526239-B1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORP (KR) 2021-11-03 EP disclosed
US-20210017215-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2021-01-21 US disclosed
US-10766916-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2020-09-08 US disclosed
US-20200157134-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2020-05-21 US disclosed
US-20190345202-A1 ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2019-11-14 US disclosed
WO-2018069764-A1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2018-04-19 WO disclosed
WO-2010067886-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed
US-7728117-B2 Heterobifunctional pan-selectin inhibitors GLYCOMIMETICS, INC. (US) 2010-06-01 US disclosed
US-20090312278-A1 TREATMENT OF CANCERS OF THE BLOOD USING SELECTED GLYCOMIMETIC COMPOUNDS GLYCOMIMETICS , INC. (US) 2009-12-17 US disclosed
US-20090253646-A1 PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY GLYCOMIMETICS, INC. (US) 2009-10-08 US disclosed
US-20090175792-A1 GLYCOMIMETIC INHIBITORS OF SIGLEC-8 GLYCOMIMETICS, INC. (US) 2009-07-09 US disclosed
US-20090036386-A1 Heterobifunctional compounds for selectin inhibition GLYCOMIMETICS, INC (US) 2009-02-05 US disclosed
US-20090023679-A1 Compounds and methods for treatment of sickle cell disease or complications associated therewith GLYCOMIMETICS, INC. (US) 2009-01-22 US disclosed
US-20080200406-A1 Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines GLYCOMIMETICS, INC. (US) 2008-08-21 US disclosed
US-20080161546-A1 Glycomimetic replacements for hexoses and N-acetyl hexosamines GLYCOMIMETICS, INC. (US) 2008-07-03 US disclosed
US-7361644-B2 Specific antagonist for both E- and P-selectins GLYCOMIMETICS, INC. (US) 2008-04-22 US disclosed